Benitec Biopharma Inc.
BNTC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BNTC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BNTC
Benitec Biopharma Inc. is a clinical-stage biotechnology company developing single-administration gene therapies based on its proprietary ddRNAi-based 'silence and replace' platform, with a lead candidate BB-301 for oculopharyngeal muscular dystrophy (OPMD).
Key risk: Clinical trial failure risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Tracking 1 clinical trial for Benitec Biopharma Inc..
Benitec Biopharma Inc. is a clinical-stage biotechnology company developing single-administration gene therapies based on its proprietary ddRNAi-based 'silence and replace' platform, with a lead candidate BB-301 for oculopharyngeal muscular dystrophy (OPMD).
- Lead candidate BB-301 is in a Phase 1b/2a clinical trial for OPMD with dysphagia, with initial patients showing durable response at 12 months [sec_mda · as of 2026-02-12].
- BB-301 has received Fast Track and Orphan Drug Designation in the U.S. and Orphan Drug Designation in the EU [sec_mda · as of 2026-02-12].
- Cash and equivalents were $184.9M as of 2026-03-31, with no revenue and a net loss of $11.9M for the quarter [sec].
- The company raised $104.5M in gross proceeds from stock issuance in the six months ended December 31, 2025 [sec_mda · as of 2026-02-12].
- Benitec does not own manufacturing facilities and relies on external partners for production of its product candidates [sec_mda · as of 2026-02-12].
What works
- Proprietary ddRNAi-based 'silence and replace' platform may enable single-administration therapies that silence disease-causing genes and replace wild-type function [sec_mda · as of 2025-05-14].
- BB-301 has shown durable clinical response at 12 months in the first 4 patients of Cohort 1, supporting potential for long-term benefit [sec_mda · as of 2026-02-12].
- Regulatory designations (Fast Track, Orphan Drug) in both U.S. and EU may accelerate development and provide market exclusivity [sec_mda · as of 2026-02-12].
- Cash position of $184.9M as of 2026-03-31 provides runway to advance clinical programs [sec].
What to weigh
- No revenue from product sales and expects continued operating losses, which may increase as development progresses [sec_mda · as of 2026-05-14].
- Dependence on external manufacturing partners for clinical and commercial supply introduces operational risk [sec_mda · as of 2026-02-12].
- Uncertainty in future funding requirements due to numerous risks in drug development and commercialization [sec_mda · as of 2026-05-14].
- BB-301 is still in early-stage clinical trials (Phase 1b/2a) with no guarantee of success or regulatory approval [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
BB-301 has shown durable response at 12 months in the first 4 patients of Cohort 1.
“the first 4 patients in Cohort 1 have now completed the 12-month statistical follow-up period and continued to demonstrate durable response to BB-301”
SEC MD&A · February 12, 2026
BB-301 has Fast Track and Orphan Drug Designation in the U.S. and Orphan Drug Designation in the EU.
“BB-301 was previously granted fast track and Orphan Drug Designation in the U.S. and Orphan Drug Designation in the European Union (EU) for the treatment of OPMD with dysphagia”
SEC MD&A · February 12, 2026
The company does not own manufacturing facilities for its product candidates.
“We do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any of our product candidates”
SEC MD&A · February 12, 2026
The company expects to continue generating losses and may use capital sooner than expected.
“we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of product candidates”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2023-11-28 · Phase 1b/2a trial start for BB-301 — A Phase 1b/2a open-label dose escalation study evaluating safety and clinical activity of BB-301 in OPMD patients is recruiting.
- 2026-05-14 · Earnings report (8-K filing) — Quarterly earnings report providing updated financials and operational progress.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — BB-301 is in Phase 1b/2a; negative results could halt development and impair value [sec_mda · as of 2026-05-14].
- Dependence on external manufacturing — No internal manufacturing; reliance on third parties for supply chain [sec_mda · as of 2026-02-12].
- No revenue and ongoing losses — No product revenue; expects increasing losses with no near-term profitability [sec_mda · as of 2026-05-14].
- Need for future financing — Cash may be insufficient to complete all programs; additional capital needed [sec_mda · as of 2026-05-14].
What to watch
- Engagement with FDA mid-2026 to confirm BB-301 pivotal study design [sec_mda · as of 2026-02-12].
- Enrollment and safety data from the ongoing Phase 1b/2a trial of BB-301 (NCT06185673) [catalyst].
- Potential partnership or licensing deals for ddRNAi platform in non-core disease areas [sec_mda · as of 2026-02-12].
- Cash burn rate and any future equity or debt financing activities [sec_mda · as of 2026-02-12].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run Benitec Biopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Benitec Biopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
124.8 months
D/E 0.02 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
87
Total value held
$370.4M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 11,548,351 | $123.0M |
| janus henderson group plc | 5,752,760 | $61.4M |
| franklin resources inc | 2,378,159 | $25.3M |
| adage capital partners gp, l.l.c. | 2,120,672 | $22.6M |
| vanguard capital management llc | 1,863,112 | $19.8M |
| ra capital management, l.p. | 1,850,000 | $19.7M |
| blackrock, inc. | 1,185,741 | $12.6M |
| infinitum asset management, llc | 923,006 | $9.8M |
| alyeska investment group, l.p. | 750,000 | $8.0M |
| silverarc capital management, llc | 717,725 | $7.6M |
Showing top 10 of 87 institutional holders of Benitec Biopharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.9%
- Days to cover
- 21.4
- Shares short
- 2,318,612
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BNTC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Benitec Biopharma Inc.?
Benitec Biopharma Inc. is a clinical-stage biotechnology company developing single-administration gene therapies based on its proprietary ddRNAi-based 'silence and replace' platform, with a lead candidate BB-301 for oculopharyngeal muscular dystrophy (OPMD).
Who is the CEO of Benitec Biopharma Inc.?
Dr. Jerel A. Banks M.D., Ph.D. is the chief executive officer of Benitec Biopharma Inc. (BNTC).
Where is Benitec Biopharma Inc. headquartered?
Benitec Biopharma Inc. (BNTC) is headquartered in Hayward, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.